Avantor, a global leader in life sciences and advanced technologies, has announced a strategic partnership with BlueWhale Bio, a commercial-stage company focused on transforming immune cell therapy manufacturing. The collaboration aims to streamline CAR-T production, reducing variability and time-to-patient while expanding access to life-saving therapies.
The partnership brings together Avantor’s bioprocessing and custom reagent manufacturing expertise with BlueWhale Bio’s Synecta™ cell-derived nanoparticle (CDNP) platform, which mimics natural T-cell stimulation. Together, the organizations will accelerate the scale-up of CDNP manufacturing and produce GMP-grade CDNP materials to support next-generation cell therapy manufacturing.
By combining technological innovation and biomanufacturing capabilities, Avantor and BlueWhale Bio aim to enhance production efficiency and capacity across the rapidly growing cell therapy sector.
